CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
D-cycloserine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00742079
NCT00742079Phase 4Completed
CompareCT.gov

Pilot Study of Pretreatment D-cycloserine for CBT-assessment of Paranoid Delusions in Schizophrenia

Massachusetts General Hospital·interventional·Posted Aug 27, 2008·Updated Dec 19, 2017

In Brief

A Phase 4 clinical trial evaluating D-cycloserine and Cognitive Behavioral Therapy for Schizophrenia. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study will examine whether pretreatment with D-cycloserine before cognitive behavioral therapy can reduce impairments still present in people with stable cases of schizophrenia as well as determine which traits make schizophrenics most likely to respond to D-cycloserine treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 27, 2008
Enrollment StartSep 1, 2006
Primary CompletionJul 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.8 years ago

Interventions

D-cycloserinedrug

Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session

Cognitive Behavioral Therapybehavioral

One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations